ABSTRACT
ZYKR1, a short chain novel peptide with selective kappa opioid receptor agonist activity used as analgesics for the treatment of pain management. A sensitive and selective LC-MS/MS assay was developed and validated for estimation of ZYKR1 in human urine and plasma. ZY17258, an analogue compound was used as an internal standard. ZYKR1 was quantified using a selective reaction monitoring in electrospray ionization positive mode. The chromatographic separation was performed using mobile phase consisted of 0.05% v/v formic acid in water and methanol in gradient elution by analytical column Kinetex C8, 100 A°, 5 µm, 100 × 4.6 mm with 8.0 min analytical run time. Solid Phase extraction technique was used for purification of ZYKR1 and IS from human urine and plasma. The calibration curves were linear over range of 0.300 ng/mL to 300 ng/mL and 0.500 ng/mL to 500 ng/mL for human urine and plasma, respectively. No matrix effect and no significant carryover were observed. The extraction recovery was consistent and ranged from about 85% to 93% in human urine and in plasma respectively. Inter-day and intra-day accuracy (bias, %) and precision (CV, %) was -11.11 to 5.91 % and -2.25 to 6.65 % in human urine and -2.74 to 7.17 % and 2.24 to 15.18 % in plasma respectively were well within the acceptance criteria. Both the assays were devoid of endogenous matrix interference and commonly used concomitant drug interference. The validated assays were used for estimation of ZYKR1 from clinical pharmacokinetic study sample bioanalysis in healthy human subjects.
Subject(s)
Analgesics/blood , Analgesics/urine , Chromatography, High Pressure Liquid/methods , Peptides/blood , Peptides/urine , Tandem Mass Spectrometry/methods , Humans , Limit of Detection , Plasma/chemistry , Receptors, Opioid, kappa/agonists , Urine/chemistryABSTRACT
Urine drug testing (UDT) is an important analytical/bio-analytical technique that has inevitably become an integral and vital part of a testing programme for diagnostic purposes. This manuscript presents a tailor-made LC-MS/MS quantitative assay method development and validation for a custom group of 33 pain panel drugs and their metabolites belonging to different classes (opiates, opioids, benzodiazepines, illicit, amphetamines, etc.) that are prescribed in pain management and depressant therapies. The LC-MS/MS method incorporates two experiments to enhance the sensitivity of the assay and has a run time of about 7 minutes with no prior purification of the samples required and a flow rate of 0.7 mL/min. The method also includes the second-stage metabolites for some drugs that belong to different classes but have first-stage similar metabolic pathways that will enable to correctly identify the right drug or to flag the drug that might be due to specimen tampering. Some real case examples and difficulties in peak picking were provided with some of the analytes in subject samples. Finally, the method was deliberated with some randomly selected de-identified clinical subject samples, and the data evaluated from "direct dilute and shoot analysis" and after "glucuronide hydrolysis" were compared. This method is now used to run routinely more than 100 clinical subject samples on a daily basis.
Subject(s)
Analgesics/urine , Antidepressive Agents/urine , Chromatography, Liquid , Drug Monitoring , Spectrometry, Mass, Electrospray Ionization , Substance Abuse Detection , Tandem Mass Spectrometry , Humans , Predictive Value of Tests , Reproducibility of Results , UrinalysisABSTRACT
Gabapentin (GBP) is an organic cation mainly eliminated unchanged in urine, and active drug secretion has been suggested to contribute to its renal excretion. Our objective was to evaluate the potential drug-drug interaction between GBP and cetirizine (CTZ), an inhibitor of transporters for organic cations. An open-label, 2-period, crossover, nonrandomized clinical trial was conducted in patients with neuropathic pain to evaluate the effect of CTZ on GBP pharmacokinetics. Twelve participants were treated with a single dose of 300 mg GBP (treatment A) or with 20 mg/d of CTZ for 5 days and 300 mg GBP on the last day of CTZ treatment (treatment B). Blood sampling and pain intensity evaluation were performed up to 36 hours after GBP administration. The interaction of GBP and CTZ with transporters for organic cations was studied in human embryonic kidney (HEK) cells expressing the organic cation transporters (OCTs), multidrug and toxin extrusion proteins (MATEs), and OCTN1. CTZ treatment resulted in reduced area under the concentration-time curve and peak concentration compared with treatment A. In treatment B, the lower plasma concentrations of GBP resulted in reduced pain attenuation. GBP renal clearance was similar between treatments. GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells. At therapeutic concentrations, CTZ interacts with hMATE1 and OCTN1. In summary, CTZ reduced the systemic exposure to GBP and its effect on neuropathic pain attenuation. However, CTZ × GBP interaction is not mediated by the renal transporters.
Subject(s)
Analgesics/pharmacokinetics , Cetirizine/metabolism , Cetirizine/pharmacokinetics , Gabapentin/pharmacokinetics , Organic Cation Transport Proteins/metabolism , Adult , Analgesics/administration & dosage , Analgesics/blood , Analgesics/urine , Area Under Curve , Cations/metabolism , Cetirizine/administration & dosage , Cross-Over Studies , Drug Interactions , Female , Gabapentin/administration & dosage , Gabapentin/blood , Gabapentin/urine , HEK293 Cells , Humans , Male , Middle Aged , Neuralgia/drug therapy , Organic Cation Transport Proteins/genetics , Organic Cation Transporter 2/genetics , Pain Measurement/drug effects , Polymorphism, Genetic , Renal Elimination/drug effects , Symporters/genetics , Symporters/metabolismABSTRACT
EMA401, (the S-enantiomer of 5-(benzyloxy)-2-(2,2-diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid), also known as Olodanrigan, is an orally active selective angiotensin II type 2 receptor (AT2 R) antagonist that is in Phase IIb clinical development as a novel analgesic for the relief of chronic pain. The main purpose of the present work was to investigate the disposition of a single 14 C- labeled EMA401 in non-clinical studies. The in vitro metabolism studies of EMA401 were undertaken to understand the hepatic biotransformation pathways in animal species used in toxicology studies and how they compare to human. Furthermore, investigation of EMA401's PK was carried out in vivo in rats. The study demonstrates the rapid absorption and distribution of drug-related material mainly to the tissues associated with absorption and elimination (GI tract, liver, and kidney). EMA401was then readily eliminated metabolically via the bile (95% of dose) predominantly in the form of the direct acylglucuronide (40% of dose), which was further hydrolysed by the intestinal flora to the active parent drug. Other metabolic pathways such as dealkylations and hydroxylation were also involved in the elimination of EMA401 to a lesser extent. EMA401 was metabolically unstable in hepatocytes of all species investigated and the key metabolites produced in the in vitro model were also detected in vivo. Independent of the dosing route, the S-enantiomer EMA401 showed a good in vivo chiral stability. Overall, the present study provides the first full characterization of the disposition of EMA401 in preclinical species.
Subject(s)
Analgesics/pharmacokinetics , Angiotensin II Type 2 Receptor Blockers/pharmacokinetics , Benzhydryl Compounds/pharmacokinetics , Isoquinolines/pharmacokinetics , Analgesics/blood , Analgesics/chemistry , Analgesics/urine , Angiotensin II Type 2 Receptor Blockers/blood , Angiotensin II Type 2 Receptor Blockers/chemistry , Angiotensin II Type 2 Receptor Blockers/urine , Animals , Benzhydryl Compounds/blood , Benzhydryl Compounds/chemistry , Benzhydryl Compounds/urine , Biotransformation , Blood Proteins/metabolism , Cells, Cultured , Dogs , Feces/chemistry , Female , Hepatocytes/metabolism , Humans , Isoquinolines/blood , Isoquinolines/chemistry , Isoquinolines/urine , Macaca fascicularis , Male , Mice, Inbred ICR , Microsomes, Liver/metabolism , Rats, Long-Evans , Rats, Sprague-Dawley , StereoisomerismABSTRACT
An electrochemical sensing platform based upon screen-printing electrodes (SPEs) modified with nanostructured lanthanide metal oxides facilitate the detection of the widely misused drugs acetaminophen (ACP) and tramadol (TRA). Among the metal oxides examined, Yb2O3 nanoplates (NPs) were found to give rise to an optimal electrochemical response. The electroanalysis of ACP and TRA individually, and within mixtures, was performed using cyclic and differential pulse voltammetry. The ACP and TRA exhibited non-overlapping voltammetric signals at voltages of +0.30 and + 0.67 V (vs. Ag/AgCl; pH 9) using Yb2O3-SPEs. Pharmaceutical dosage forms and spiked human fluids were analyzed in wide linear concentration ranges of 0.25-654 and 0.50-115 µmol.L-1 with limits of detection (LOD) of 55 and 87 nmol.L-1 for ACP and TRA, respectively. The Yb2O3-SPEs offer a sensitive and chemically stable enzyme-free electrochemical platform for ACP and TRA assay. Graphical abstractSchematic presentation of one-shot electrochemical analysis of misused drugs, tramadol (TRA) and acetaminophen (ACP) by utilizing ytterbium oxide nanoplates modified screen-printed electrodes (Yb2O3-SPEs). The Yb2O3-SPEs showed interesting responses for ACP and TRA within pharmaceutical formulations and human fluids.
Subject(s)
Acetaminophen/analysis , Analgesics/analysis , Nanostructures/chemistry , Oxides/chemistry , Tramadol/analysis , Ytterbium/chemistry , Acetaminophen/blood , Acetaminophen/urine , Analgesics/blood , Analgesics/urine , Electrochemical Techniques/instrumentation , Electrochemical Techniques/methods , Electrodes , Humans , Limit of Detection , Reproducibility of Results , Tramadol/blood , Tramadol/urineABSTRACT
Supercritical fluid chromatography (SFC) holds the potential to become an orthogonal method to HPLC/UHPLC in xenobiotic metabolism studies, due to its outstanding capacity to simultaneously separate highly similar (as HPLC) and physicochemically different analytes (problematic using HPLC). Paucity of guideline-conform validation, however, has been a major obstacle to clinical application of SFC, even in cases where biotransformation yields chemically dissimilar metabolites that require more than one HPLC method for comprehensive analysis. Here, a method based on supercritical fluid chromatography coupled to single quadrupole MS detection was developed to simultaneously quantify the divisive analgesic flupirtine and its acidic and basic metabolites, represented by 4-fluorohippuric acid (4-FHA) and the active metabolite D-13223 respectively, using custom-made synthetic internal standards. Experimental data on the fundamental retention mechanisms under supercritical conditions, indicating the importance of halogen and π-π-bonding for specific retention on polysaccharide-based stationary-phases, is discussed. Compared to previous HPLC methods, the novel method offers higher versatility in terms of the target metabolite range (addressing both acidic and basic metabolites within a singular method), faster analysis (7.5 min), and compliance with green chemistry principles. Validation was performed according to EMA criteria on bioanalytical method validation, demonstrating selectivity, carry-over, calibration curve parameters (LLOQ, range, and linearity), within- and between-run accuracy and precision, dilution integrity, matrix effect and stability. For proof-of-concept, the SFC method was applied to clinical samples of human urine obtained after single intravenous (100 mg), single oral (100 mg), and repeated oral administration (400 mg). Flupirtine, D-13223, and 4-FHA could be quantified, shedding light on the extent of oxidative flupirtine metabolism in humans in the context of the unresolved biotoxification that has led to the withdrawal of specific neuronal KV7 openers.
Subject(s)
Acids/chemistry , Aminopyridines/analysis , Chromatography, Supercritical Fluid/methods , Metabolome , Adult , Aminopyridines/pharmacology , Aminopyridines/urine , Analgesics/pharmacology , Analgesics/urine , Calibration , Europe , Female , Humans , Limit of Detection , Male , Reproducibility of Results , Solvents , Temperature , Young AdultABSTRACT
A fast and simple approach to overcome challenges in emergency toxicological analysis, using ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) has been developed, for the detection of analytes in blood and urine samples from the following drug classes: analgesics, benzodiazepines, antidepressants, anticonvulsants, drugs of abuse, and pesticides. These substances are relevant in the context of emergency toxicology in Brazil. The sample preparation procedure was relatively easy and fast to perform. The method was fully validated giving limits of in the range of 0.5 and 20 ng mL-1 for blood and urine samples. The intraday and interday precision and accuracy were considered adequate for all analytes once the relative standard deviation (RSD) (%) was lower than 20% for quality control (QC) low and lower than 15% for CQ medium and high. The developed method was successfully applied to 320 real samples collected at the Poison Control Center of São Paulo, and 89.1% have shown to be positive for some of the analytes. This confirms its applicability and importance to emergency toxicological analysis, and it could be very useful in both fields of clinical and forensic toxicology.
Subject(s)
Illicit Drugs/blood , Illicit Drugs/urine , Pesticides/blood , Pesticides/urine , Pharmaceutical Preparations/blood , Pharmaceutical Preparations/urine , Analgesics/blood , Analgesics/urine , Anticonvulsants/blood , Anticonvulsants/urine , Antidepressive Agents/blood , Antidepressive Agents/urine , Benzodiazepines/blood , Benzodiazepines/urine , Brazil , Chromatography, High Pressure Liquid , Humans , Limit of Detection , Tandem Mass SpectrometryABSTRACT
An environmentally friendly thermosensitive nanovesicle-cloud point microextraction technique has been developed with the assistant of ultrasonic waves to determine analgesic drugs with a broad range of polarity in field water and human urine. Based on thin-film hydration, the conformation of nanovesicles formed by a binary mixing system with the nonionic surfactants was evaluated using regular and cryogenic transmission electron microscopy. The multilayered nano-spherical structure was able to capture polar and nonpolar compounds simultaneously. Analgesic drugs (acetaminophen, salicylic acid, ketoprofen, diclofenac, indomethacin, ibuprofen, and mefenamic acid) were detected by ultra-performance liquid chromatography coupled to photodiode array detection. Under optimal conditions including the type and ratio of surfactants, sonication time and sonication temperature, linear calibration curves were obtained over the range of 50-8000⯵g L-1. The coefficient of determination (R2) ranged from 0.9953 to 0.9995, with detection limits of 10-100⯵g L-1. The relative standard deviations ranged from 3.2% to 12.7% for intraday precision (nâ¯=â¯5) and 2.5% to 14.1% for interday precision (nâ¯=â¯15). The relative recoveries obtained from one industrial wastewater sample and two field water samples ranged from 86.1% to 108.1%. In the human urine analysis, three volunteers ingested 1500â¯mg of acetaminophen. After 4â¯h, the concentration of acetaminophen in the urine was found to range from 87.0 to 197.9â¯mg L-1.
Subject(s)
Analgesics/isolation & purification , Analgesics/urine , Chemical Fractionation/methods , Nanostructures/chemistry , Sewage/chemistry , Sonication , Temperature , Chemistry Techniques, Synthetic , Environment , Humans , Hydrogen-Ion Concentration , Nanotechnology , Reproducibility of Results , Sodium Chloride/chemistry , Time FactorsABSTRACT
It is well known that the sample correlation coefficient (Rxy ) is the maximum likelihood estimator of the Pearson correlation (ρxy ) for independent and identically distributed (i.i.d.) bivariate normal data. However, this is not true for ophthalmologic data where X (e.g., visual acuity) and Y (e.g., visual field) are available for each eye and there is positive intraclass correlation for both X and Y in fellow eyes. In this paper, we provide a regression-based approach for obtaining the maximum likelihood estimator of ρxy for clustered data, which can be implemented using standard mixed effects model software. This method is also extended to allow for estimation of partial correlation by controlling both X and Y for a vector U_ of other covariates. In addition, these methods can be extended to allow for estimation of rank correlation for clustered data by (i) converting ranks of both X and Y to the probit scale, (ii) estimating the Pearson correlation between probit scores for X and Y, and (iii) using the relationship between Pearson and rank correlation for bivariate normally distributed data. The validity of the methods in finite-sized samples is supported by simulation studies. Finally, two examples from ophthalmology and analgesic abuse are used to illustrate the methods. Copyright © 2017 John Wiley & Sons, Ltd.
Subject(s)
Likelihood Functions , Analgesics/urine , Biostatistics , Computer Simulation , Data Interpretation, Statistical , Humans , Models, Statistical , Ophthalmology/statistics & numerical data , Regression Analysis , Retinitis Pigmentosa/physiopathology , Sample Size , Software , Substance-Related Disorders/urine , Visual Acuity , Visual FieldsABSTRACT
A common treatment for chronic pain is prescription of analgesics, but their long-term use entails risk of morbidity, addiction and misuse. One way to reduce the risk of abuse is prescribing of analgesics in a topical form. Physicians are urged to perform urine drug testing to ensure that patients are compliant with their medication regimens. However, there is little data on the efficiency of transdermal delivery for many analgesic drugs, and no data on expected urine drug levels. This study includes data from over 29,000 specimens tested for gabapentin, ketamine, cyclobenzaprine or amitriptyline used orally or topically. Gabapentin and amitriptyline concentrations were more likely to be below the limits of detection (25-40 ng/mL) in the urine of patients using them topically as compared with patients using them orally. Levels in gabapentin-positive topical specimens were much lower than in gabapentin-positive oral specimens (261 ng/mL vs >10,000 ng/mL). In contrast, ketamine and cyclobenzaprine were more readily detectable in the urine of topical users. Ketamine topical specimens were positive 12% more often than oral specimens, and mean topical specimen levels were 68-100% those of oral specimens. Cyclobenzaprine specimens were equally likely to be positive whether the dose was oral or topical, although mean levels after topical dosing were approximately 13-21% those after oral dosing. These findings are consistent with the reported percutaneous absorption efficiencies of gabapentin and ketamine, and are likely to be related to the absorption efficiencies of cyclobenzaprine and amitriptyline.
Subject(s)
Analgesics/administration & dosage , Analgesics/urine , Drug Monitoring/methods , Substance Abuse Detection/methods , Administration, Oral , Administration, Topical , Amines/administration & dosage , Amines/therapeutic use , Amines/urine , Amitriptyline/administration & dosage , Amitriptyline/analogs & derivatives , Amitriptyline/therapeutic use , Amitriptyline/urine , Analgesics/therapeutic use , Chronic Pain/drug therapy , Chronic Pain/urine , Cyclohexanecarboxylic Acids/administration & dosage , Cyclohexanecarboxylic Acids/therapeutic use , Cyclohexanecarboxylic Acids/urine , Drug Monitoring/instrumentation , Gabapentin , Humans , Ketamine/administration & dosage , Ketamine/therapeutic use , Ketamine/urine , Limit of Detection , Skin Absorption , Substance Abuse Detection/instrumentation , gamma-Aminobutyric Acid/administration & dosage , gamma-Aminobutyric Acid/therapeutic use , gamma-Aminobutyric Acid/urineABSTRACT
Butalbital, a barbiturate, is present in analgesic combinations used by headache sufferers. Overuse/abuse of these combinations may cause dependence, chronic migraine, and medication-overuse headache (MOH). MOH is difficult to manage: it improves interrupting analgesic overuse, but requires monitoring, because relapses are frequent. A gas chromatography-mass spectrometry (GC-MS) method for hair analysis has been developed and validated to document abuse of an analgesic combination containing butalbital and propyphenazone by a patient with MOH. For over ten years the patient managed her headache using eight suppositories/day of an analgesic combination containing butalbital 150mg, caffeine 75mg, and propyphenazone 375mg per suppository. An outpatient detoxification treatment was carried out. After three weeks, the patient reduced the consumption to one suppository/day. At the first control visit, after three months from the beginning of detoxification, the patient increased the use of the combination to four suppositories/day and at the second control visit, after seven months from the beginning of detoxification, she was back to eight suppositories/day. At the two control visits, a hair sample was taken for determination of butalbital and propyphenazone. Moreover blood and urine samples for determination of butalbital were drawn at the beginning of detoxification treatment and at the two control visits. With the segmental analysis of two hair samples the medication history of ten months could be estimated. In the first hair sample, collected at the first control visit, in the distal segment, butalbital and propyphenazone concentrations were, respectively, 17.5ng/mg and 56.0ng/mg, confirming the prolonged abuse; in the proximal segment, concurrently with the detoxification treatment, butalbital and propyphenazone concentrations had reduced respectively to 5.45ng/mg and 11.1ng/mg. The second hair sample, collected at the second control visit, proved the fair course of the detoxification treatment in the distal segment and signalled relapse in the abuse of the analgesic combination in the proximal segment. In the clinical context, hair analysis can be advantageously used to monitor the abuse of analgesic combinations with butalbital, common among headache patients. The validation data showed that GC-MS method developed for determination of butalbital and propyphenazone was rapid, highly sensitive, specific and selective.
Subject(s)
Analgesics/metabolism , Antipyrine/analogs & derivatives , Barbiturates/metabolism , Gas Chromatography-Mass Spectrometry , Hair/metabolism , Headache Disorders, Secondary/diagnosis , Substance Abuse Detection/methods , Substance-Related Disorders/diagnosis , Aged , Analgesics/blood , Analgesics/urine , Antipyrine/metabolism , Barbiturates/blood , Barbiturates/urine , Drug Combinations , Female , Headache Disorders, Secondary/metabolism , Headache Disorders, Secondary/therapy , Humans , Predictive Value of Tests , Recurrence , Reproducibility of Results , Substance-Related Disorders/metabolism , Substance-Related Disorders/therapy , Time FactorsABSTRACT
A novel LC-MS-MS assay that simultaneously detects and quantitates 78 drugs and metabolites was developed and validated for chronic pain management. Urine specimen was diluted and mixed with internal standards (ISs) before injected into LC-MS-MS. Seventy-two analytes were detected with positive electrospray ionization mode and the remaining six analytes with negative mode. Two separate gradient elution chromatographic programs were established with the same mobile phases on the same bi-phenyl HPLC column. The assay was linear for all analytes with linear regression coefficient ranging 0.994-1.000. The intra-assay precision was between 1.7 and 8.8% and inter-assay precision between 1.9 and 12.2%, with bias <20% for all but six analytes. All analytes in urine specimens were stable for 7 days at 4°C, and no significant matrix effect or carryover was observed. A suboptimal recovery rate (60.0-156.8%) was observed for six analytes, potentially due to the lack of available deuterated ISs, requiring comparison to a chemically different IS. Method comparison using patient and proficiency testing samples demonstrated that this assay was sensitive and accurate. The assay improves on currently existing assays by including glucuronide conjugates, allowing direct detection of metabolites that might otherwise be missed by existing methods.
Subject(s)
Analgesics/therapeutic use , Analgesics/urine , Chromatography, Liquid , Chronic Pain/drug therapy , Chronic Pain/urine , Drug Monitoring/methods , High-Throughput Screening Assays , Tandem Mass Spectrometry , Biomarkers/urine , Biotransformation , Calibration , Chromatography, Liquid/standards , Chronic Pain/diagnosis , Drug Monitoring/standards , Drug Stability , High-Throughput Screening Assays/standards , Humans , Limit of Detection , Linear Models , Predictive Value of Tests , Reference Standards , Reproducibility of Results , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry/standards , Temperature , Time FactorsABSTRACT
OBJECTIVES: The major objective of this research was to propose a simplified approach for the evaluation of medication adherence in chronic pain management patients, using liquid chromatography time-of-flight (TOF) mass spectrometry, performed in parallel with select homogeneous enzyme immunoassays (HEIAs). We called it a "hybrid" approach to urine drug testing. METHODS: The hybrid approach was defined based on anticipated positivity rates, availability of commercial reagents for HEIAs, and assay performance, particularly analytical sensitivity and specificity for drug(s) of interest. Subsequent to implementation of the hybrid approach, time to result was compared with that observed with other urine drug testing approaches. RESULTS: Opioids, benzodiazepines, zolpidem, amphetamine-like stimulants, and methylphenidate metabolite were detected by TOF mass spectrometry to maximize specificity and sensitivity of these 37 drug analytes. Barbiturates, cannabinoid metabolite, carisoprodol, cocaine metabolite, ethyl glucuronide, methadone, phencyclidine, propoxyphene, and tramadol were detected by HEIAs that performed adequately and/or for which positivity rates were very low. Time to result was significantly reduced compared with the traditional approach. CONCLUSIONS: The hybrid approach to urine drug testing provides a simplified and analytically specific testing process that minimizes the need for secondary confirmation.
Subject(s)
Analgesics/urine , Chronic Pain/drug therapy , Medication Adherence , Substance Abuse Detection/methods , Analgesics/therapeutic use , Humans , Immunoassay , Retrospective Studies , Spectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationABSTRACT
Various studies pointed towards a relationship between chronic diseases such as asthma and allergy and environmental risk factors, which are one aspect of the so-called Exposome. These environmental risk factors include also the intake of drugs. One critical step in human development is the prenatal period, in which exposures might have critical impact on the child's health outcome. Thereby, the health effects of drugs taken during gestation are discussed controversially with regard to newborns' disease risk. Due to this, the drug intake of pregnant women in the third trimester was monitored by questionnaire, in addition to biomonitoring using a local birth cohort study, allowing correlations of drug exposure with disease risk. Therefore, 622 urine samples were analyzed by an untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) urine screening and the results were compared to self-administered questionnaires. In total, 48% (n = 296) reported an intake of pharmaceuticals, with analgesics as the most frequent reported drug class in addition to dietary supplements. 182 times compounds were detected by urine screening, with analgesics (42%; n = 66) as the predominantly drug class. A comparison of reported and detected drug intake was performed for three different time spans between completion of the questionnaires and urine sampling. Even if the level of accordance was low in general, similar percentages (~25%, ~19%, and ~ 20%) were found for all groups. This study illustrates that a comprehensive evaluation of drug intake is neither achieved by questionnaires nor by biomonitoring alone. Instead, a combination of both monitoring methods, providing complementary information, should be considered.
Subject(s)
Drug Monitoring/methods , Pharmaceutical Preparations/urine , Tandem Mass Spectrometry/methods , Urinalysis/methods , Analgesics/urine , Chromatography, Liquid/methods , Female , Humans , Pregnancy , Prospective Studies , Surveys and QuestionnairesABSTRACT
Urine specimens submitted for pain management drug testing often contain multiple psychotherapeutic drugs, in addition to opioids. Immunoassay-based screen-and-confirm approaches typically used for clinical drug testing have limited sensitivity to detect therapeutic concentrations of many drugs prescribed in pain management and do not differentiate between drugs in the same class. In addition, screening for all the various illicit and prescription drugs that may be present in the pain management population requires as many as 10-20 individual immunoassays. High-resolution MS approaches have the potential to transform the way clinical drug testing is performed for pain management.
Subject(s)
Analgesics/urine , Mass Spectrometry , Analgesics/therapeutic use , Benzodiazepines/urine , Drug Monitoring , Humans , Immunoassay , Pain/drug therapy , Pain ManagementABSTRACT
BACKGROUND: Despite hints about the high incidence of pain patients misreporting their pain medication use, there are only a few non-controlled studies on the topic that focus solely on opioids. OBJECTIVE: Using toxicological analyses in a cross-sectional study, we investigated patients' reliability regarding their report of any current pain medication use. STUDY DESIGN: A cross-sectional study. SETTING: A comprehensive pain center and a surgical unit of a German University Hospital. METHODS: Consecutive outpatients at their first visit to the pain clinic (PG, n = 243) and pre-surgical control patients (SG, n = 100) suffering from pain reported on their current pain medication. The patients' reports were verified in serum and urine using specific toxicological methods. Two types of noncompliance were defined: under-reporting (detection of non-reported substances) and over-reporting (reported substances undetectable). The impact of clinical parameters on compliance was investigated using binary logistic regression. RESULTS: The incidence of noncompliance was significantly higher in the PG (43.3%) than in the SG (24%; P < 0.05). Under-reporting occurred similarly in both groups (31% PG; 23% SG), whereas over-reporting predominantly appeared in the PG (11% vs. 2%; P < 0.05). Opioids were not most frequently under-reported, but the highest proportion of under-reported drugs (under-reported in relation to detection incidence) was found for non-opioid analgesics (NSAIDs: 29% PG; 25% SG; other: 42% PG; 32% SG) and psychotropic drugs (35% PG; 53% SG). In the PG, logistic regression revealed high depression scores to be predictive for noncompliance (odds ratio 2.12). LIMITATIONS: Due to lack of a structured follow-up interview motives of under- and over-reporting stay speculative. CONCLUSIONS: Under-reporting of non-opioid analgesics is the main type of noncompliance, a disquieting fact in light of their toxicity and adverse effects. Further research is required in terms of drug assessment and compliance improvement strategies in pain clinics; therefore, toxicological monitoring is indispensable. CLINICAL TRIAL: NCT01625065; Medi-3889-10.
Subject(s)
Chronic Pain/psychology , Chronic Pain/therapy , Patient Compliance/psychology , Adolescent , Adult , Aged , Aged, 80 and over , Analgesics/blood , Analgesics/therapeutic use , Analgesics/urine , Chronic Pain/blood , Chronic Pain/urine , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Pain Clinics , Pain Measurement , Reproducibility of Results , Statistics, Nonparametric , Surveys and Questionnaires , Young AdultABSTRACT
BACKGROUND: Combination drug therapy is often used to achieve optimal analgesia in surgery. Paracetamol can be used as one component of an analgesic regime following hepatic resection. OBJECTIVE: This study was designed to investigate paracetamol and its metabolites by proton NMR spectroscopy in patient urine and to assess whether N-acetyl-p-benzoquinone imine (NAPQI, a hepatotoxic metabolite) formation is increased after liver resection. METHOD: We studied the excretion of acetaminophen and its metabolites by 5 patients who were operated on for partial liver resection by proton NMR spectroscopy. As an intravenous infusion 1 g of paracetamol was given over 15 min every 6 h during 48 h. The first injection was given in the operating theatre after liver resection was completed. Urine samples were collected before injection (T1) and 24 and 48 h after the first injection (T2 and T3); the samples were frozen and kept at -20°C up to the analysis by NMR spectroscopy. RESULTS: Metabolites of the paracetamol were detected for all patients. Among the discerned metabolites, 4 were identified as metabolites of paracetamol: paracetamol glucuronide, paracetamol sulfate, N-acetyl-L-cysteinyl paracetamol (metabolite of NAPQI) and paracetamol. Their ratios, respectively, were: 46-82.9, 12.6-30.0, 0.5-5.5 and 1.43-3.54%. CONCLUSION: This study showed that there was no increase in the formation of toxic metabolite (NAPQI) after treatment with paracetamol in these few cases of liver resections. A larger study is necessary to confirm these results.
Subject(s)
Acetaminophen/pharmacokinetics , Analgesics/pharmacokinetics , Liver/metabolism , Liver/surgery , Acetaminophen/analogs & derivatives , Acetaminophen/urine , Analgesics/urine , Benzoquinones/urine , Female , Humans , Imines/urine , Magnetic Resonance Spectroscopy , Male , Middle AgedABSTRACT
Opioids are some of the most commonly prescribed and abused drugs around the world. Primarily used for anesthesia or pain management, other opioids can also be used in the treatment of opioid addiction. Given these facts, clinicians often randomly test or monitor their patients to determine compliance or abstinence from these drugs via immunoassay methods. When a positive screen is obtained, a confirmatory assay is carried out and although the gold standard has been GC-MS, LC-MS/MS is fast becoming a valid and popular alternative. This review will discuss opioids, the complex metabolic pathways, the measurement of these drugs, the challenges involved and, finally, will describe some LC-MS/MS methods published from 2003 until 2013.
Subject(s)
Analgesics, Opioid/urine , Analgesics/urine , Chromatography, Liquid/methods , Tandem Mass Spectrometry/methods , Analgesics/chemistry , Analgesics/metabolism , Analgesics, Opioid/chemistry , Analgesics, Opioid/metabolism , Animals , HumansABSTRACT
BACKGROUND: It can be challenging to successfully monitor medication compliance in pain management. Clinicians and laboratorians need to collaborate to optimize patient care and maximize operational efficiency. The test menu, assay cutoffs, and testing algorithms utilized in the urine drug testing panels should be periodically reviewed and tailored to the patient population to effectively assess compliance and avoid unnecessary testing and cost to the patient. OBJECTIVE: Pain management and pathology collaborated on an important quality improvement initiative to optimize urine drug testing for monitoring medication compliance in pain management. METHODS: We retrospectively reviewed 18 months of data from our pain management center. We gathered data on test volumes, positivity rates, and the frequency of false positive results. We also reviewed the clinical utility of our testing algorithms, assay cutoffs, and adulterant panel. In addition, the cost of each component was calculated. RESULTS: The positivity rate for ethanol and 3,4-methylenedioxymethamphetamine were <1% so we eliminated this testing from our panel. We also lowered the screening cutoff for cocaine to meet the clinical needs of the pain management center. In addition, we changed our testing algorithm for 6-acetylmorphine, benzodiazepines, and methadone. For example, due the high rate of false negative results using our immunoassay-based benzodiazepine screen, we removed the screening portion of the algorithm and now perform benzodiazepine confirmation up front in all specimens by liquid chromatography-tandem mass spectrometry. CONCLUSION: Conducting an interdisciplinary quality improvement project allowed us to optimize our testing panel for monitoring medication compliance in pain management and reduce cost.
Subject(s)
Analgesics/urine , Medication Adherence , Pain Management/methods , Pain/drug therapy , Substance Abuse Detection/methods , Humans , Retrospective StudiesABSTRACT
PURPOSE: Pregabalin is a novel GABA-analogue approved for the treatment of partial onset seizures, neuropathic pain, and general anxiety disorder. Pregabalin has been classified as a Schedule V drug with a low risk of inflicting abuse or addiction. However, some publications have indicated that pregabalin may have a potential for abuse among patients with past or current opiate addiction. Thus, we hypothesized that pregabalin might be abused by patients who were undergoing an opiate replacement therapy and never had an indication for taking pregabalin on medical grounds. METHODS: Urine specimens from 124 patients with opiate dependency syndrome and from 111 patients with other addiction disorders (alcohol, benzodiazepines, cannabis, amphetamines) were screened for pregabalin by means of a mass spectrometer analysis. RESULTS: We found 12.1 % of all urine specimens from patients with opiate addiction to be positive for pregabalin. None of the patients concerned had a medical indication for using pregabalin. In the control group, 2.7 % of the patients were tested positively for pregabalin, due to their taking it regularly for chronic pain or general anxiety. CONCLUSIONS: Our data suggest that pregabalin is liable to be abused among individuals with opiate dependency syndrome Thus, vigilance and caution are called for when patients with a past or current opiate dependency are exposed to treatment with pregabalin.